Race-based therapeutics.

@article{Bloche2004RacebasedT,
  title={Race-based therapeutics.},
  author={M. Gregg Bloche},
  journal={The New England journal of medicine},
  year={2004},
  volume={351 20},
  pages={
          2035-7
        }
}
  • M. Bloche
  • Published 11 November 2004
  • Medicine
  • The New England journal of medicine
Are we moving into a new era of race-based therapeutics? Dr. M. Gregg Bloche asserts that greater awareness that race is at best a placeholder for other predispositions, and not a biologic verity, would be a first step. 
View on PubMed
courses.ahc.umn.edu
145 Citations
Highly Influential Citations
2
Background Citations
27
Methods Citations
3
Results Citations
1

145 Citations

Pharmacogenomics: Reflecting on the Old and New Social, Ethical and Policy Issues in Postgenomics Medicine

Whenever a new form of biotechnology is introduced, there is often uncertainty around its intended and unintended impacts on science, medicine and society. Past experiences with genetically modified o

Beyond Best Practices: Strict Scrutiny as a Regulatory Model for Race-Specific Medicines

TLDR
It may be useful for the FDA to turn to an area with experience negotiating such dilemmas — constitutional law — and its approach — strict scrutiny — to help guide when and under which circumstances government should give effect to racial categories in biomedicine.

The race to prescribe: Drug for African Americans may debut amid debate

Identifying such inequalities is one step toward helping each population get appropriate medical care. Sometimes, that requires making the same tests and treatments available across the board, but it…

Race and end‐stage renal disease in the United States Medicare population: The disparity persists

TLDR
Whether racial disparities in end‐stage renal disease in the United States have changed over time has been studied to determine.

The A-HeFT Trial: More Questions than Answers

TLDR
This continuing feature will update readers on recent developments in cardiovascular pharmacotherapy, as well as encouraging pharmacists to keep current with developments in drug therapy.

BiDil: Assessing a Race-Based Pharmaceutical

TLDR
The negative aspects of BiDil and the process that led to its discovery and marketing set an unfortunate precedent, and primary care physicians should be aware of possible generic equivalents that will affect the availability of this drug for low-income or uninsured patients.

Race, Money and Medicines

  • M. G. Bloche
  • Medicine
    The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics
  • 2006
TLDR
This essay argues that the authors should start with a presumption against racial categories in medicine, but permit their use when it might prolong lives or meaningfully improve health, and follow-up inquiry into the factors that underlie race-correlated clinical differences is important.

Race‐based therapeutics A discussion surrounding heart failure trials

  • Natalie Schmitz
  • Medicine
    JAAPA : official journal of the American Academy of Physician Assistants
  • 2007
TLDR
Alarmingly, blacks comprise the largest percentage of those with these forms of CVD, and they die disproportionately compared to other racial groups, and the differences in response to drug therapies that are garnering extra attention and that have provoked a discussion regarding race-based therapies.

Racial medicine: here to stay?

TLDR
Now that the human genome sequence is complete, several follow‐up genomic projects, most notably the HapMap initiative to identify and catalogue haplotypes, are focusing on identifying such genetic variants, but it is not yet clear whether this knowledge will lead to personalized medicine.

BiDil in the Clinic: An Interdisciplinary Investigation of Physicians’ Prescription Patterns of a Race-Based Therapy

TLDR
Overall, physicians prescribe and are willing to prescribe BiDil more to black patients than to white patients, and physicians’ lack of awareness about the controversial scientific status of A-HeFT suggests the need for more efficient ways to convey scientific information about BiDIL to clinicians.
...

References

SHOWING 1-7 OF 7 REFERENCES

How a drug becomes "ethnic": law, commerce, and the production of racial categories in medicine.

  • J. Kahn
  • Medicine
    Yale journal of health policy, law, and ethics
  • 2004
TLDR
This article is a retrospective analysis of how law, commerce, science, and medicine interacted to produce a distinctive understanding of BiDil as an ethnic drug, shaping which questions got asked at critical junctures in its development and orienting how they were pursued.

Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group.

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure.

TLDR
The different effects of the two regimens (enalapril and hydralazine-isosorbide dinitrate) on mortality and physiologic end points suggest that the profile of effects might be enhanced if the regimens were used in combination.

Combination of isosorbide dinitrate and hydralazine in blacks with heart failure.

TLDR
The addition of a fixed dose of isosorbide dinitrate plus hydralazine to standard therapy for heart failure including neurohormonal blockers is efficacious and increases survival among black patients with advanced heart failure.

The Nazi Doctors: Medical Killing and the Psychology of Genocide

TLDR
This book discusses Euthanasia, Sterilization and the Nazi Biomedical Vision, and the Auschwitz Self: Psychological Themes in Doubling.

Social Isolation and Health, with an Emphasis on Underlying Mechanisms

TLDR
While socially isolated young adults did not report more frequent everyday stressors, they rated everyday events as more intensely stressful and exhibited less efficacious repair and maintenance of physiological functioning, including slower wound healing and poorer sleep efficiency.

A comparison of enalapril with hydralazineisosorbide dinitrate in the treatment of chronic congestive heart failure

  • N Engl J Med
  • 1991